# Alkermes

Type: Company (ALKS)

Source: GetYourBrief — https://getyourbrief.com/entity/alkermes
Canonical HTML page: https://getyourbrief.com/entity/alkermes

## Recent coverage (3 stories, network-wide)

### AI and CTV Pivot: Q4 Earnings Reveal a New Era of Operational Scale
2026-02-26 00:20:35 · Sector: startups · Sentiment: Positive · Impact: 7/10 · Sources: 20

The Q4 2025 earnings cycle marks a definitive shift as AI transitions from experimental to a core revenue driver, while Connected TV officially surpasses legacy digital display. High-growth sectors like InsurTech and Stablecoins are reporting massive scale-up through strategic OEM and platform partnerships.
Full story: https://getstartupbrief.com/story/q4-2025-earnings-ai-ctv-market-trends

### Rare Disease Commercialization and M&A Drive Mid-Cap Biotech Growth
2026-02-26 00:13:15 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 20

Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
Full story: https://getbiobrief.com/story/biotech-pharma-earnings-analysis-q4-2025

### Health Tech Earnings: AI Integration and Orphan Drugs Drive Q4 Sector Growth
2026-02-26 00:12:35 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 20

The Q4 2025 earnings cycle for healthcare and health IT firms reveals a sector-wide shift toward AI-driven diagnostics and high-margin orphan drug commercialization. While medical device firms face cyclical equipment sales challenges, specialized biotech and diagnostic players like Veracyte and Soleno are reporting record profitability and rapid market penetration.
Full story: https://gethealthbrief.com/story/healthcare-health-it-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.